<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">Molecules</span><span class="iso-abbrev" title="iso-abbrev">Molecules</span><span class="publisher-id" title="publisher-id">molecules</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Molecules</span></div><span class="issn-epub" tagx="issn" title="issn-epub">1420-3049</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">MDPI</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7587964">7587964</a></span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.3390/molecules25204821">10.3390/molecules25204821</a></span><span class="publisher-id" title="publisher-id">molecules-25-04821</span><div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Review</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Chronological Review and Rational and Future Prospects of Cannabis-Based Drug Development</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Namdar</span><span class="given-names" tagx="given-names" title="given-names">Dvora</span></span><a href="#af1-molecules-25-04821">1</a></span><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0002-9500-7584</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Anis</span><span class="given-names" tagx="given-names" title="given-names">Omer</span></span><a href="#af2-molecules-25-04821">2</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Poulin</span><span class="given-names" tagx="given-names" title="given-names">Patrick</span></span><a href="#af3-molecules-25-04821">3</a><a href="#af4-molecules-25-04821">4</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Koltai</span><span class="given-names" tagx="given-names" title="given-names">Hinanit</span></span><a href="#af1-molecules-25-04821">1</a><a href="#c1-molecules-25-04821">*</a></span></div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">BusardÃ²</span><span class="given-names" tagx="given-names" title="given-names">Francesco Paolo</span></span><span class="role" tagx="role" title="role">Academic Editor</span></span></div><span class="citation_author_institution" id="af1-molecules-25-04821">[1], <span class="email" tagx="email" title="email">dvoran@volcani.agri.gov.il</span></span><span class="citation_author_institution" id="af2-molecules-25-04821">[2], <span class="email" tagx="email" title="email">omerwn@gmail.com</span></span><span class="citation_author_institution" id="af3-molecules-25-04821">[3], <span class="email" tagx="email" title="email">patrick.poulin.4@umontreal.ca</span></span><span class="citation_author_institution" id="af4-molecules-25-04821">[4], </span><div class="author-notes" title="author-notes"> <div class="corresp" title="corresp"><span class="label" tagx="label" title="label">*</span>Correspondence: <span class="email" tagx="email" title="email">hkoltai@agri.gov.il</span>; Tel.: +972-3-9683039</div> </div><span class="pub-date-epub" title="pub-date-epub">epub: <span>2020-10-10</span></span><span class="pub-date-collection" title="pub-date-collection">collection: <span>2020-10</span></span><span class="volume" tagx="volume" title="volume">25</span><span class="issue" tagx="issue" title="issue">20</span><span class="elocation-id" tagx="elocation-id" title="elocation-id">4821</span><span class="history" title="history"><span class="received" title="received">received: 2020-8-30</span><span class="accepted" title="accepted">accepted: 2020-10-16</span></span><div class="permissions"><span class="copyright" title="copyright">(C) , <span class="copyright-year" tagx="copyright-year" title="copyright-year">2020</span></span><span class="license" title="license"><span class="license-p" title="license-p">Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>).</span></span></div> <div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <p>Despite the surge in cannabis chemistry research and its biological and medical activity, only a few cannabis-based pharmaceutical-grade drugs have been developed and marketed to date. Not many of these drugs are Food and Drug Administration (FDA)-approved, and some are still going through regulation processes. Active compounds including cannabinergic compounds (i.e., molecules targeted to modulate the endocannabinoid system) or phytocannabinoid analogues (cannabinoids produced by the plant) may be developed into single-molecule drugs. However, since in many cases treatment with whole-plant extract (whether as a solvent extraction, galenic preparation, or crude oil) is preferred over treatment with a single purified molecule, some more recently developed cannabis-derived drugs contain several molecules. Different combinations of active plant ingredients (API) from cannabis with proven synergies may be identified and developed as drugs to treat different medical conditions. However, possible negative effects between cannabis compounds should also be considered, as well as the effect of the cannabis treatment on the endocannabinoid system. FDA registration of single, few, or multiple molecules as drugs is a challenging process, and certain considerations that should be reviewed in this process, including issues of drugâ€"drug interactions, are also discussed here.</p> </div> <div class="kwd-group"> <div class="kwd" title="kwd">
cannabis</div> <div class="kwd" title="kwd">
cannabinergic</div> <div class="kwd" title="kwd">
drug</div> <div class="kwd" title="kwd">
FDA-approved</div> <div class="kwd" title="kwd">
medical conditions</div> <div class="kwd" title="kwd">
pharmaceutical-grade</div> <div class="kwd" title="kwd">
phytocannabinoid</div> </div> </div> </div> <div class="body" title="body"> <div class="intro" title="intro"> <div class="title" tagx="title" title="title">
1. Introduction</div> <div class="1.1.motivation" title="sec"> <div class="title" tagx="title" title="title">
1.1. Motivation</div> <p>This review aims to explore the chronology, as well as rational and future prospects, of cannabis-based drug development. The chronological path toward the development of cannabis-based drugs reflects the understanding and accumulating knowledge regarding active compounds and their mode of action. Translating these values into modern, registered, pharmaceutical drugs is a highly challenging task. For the scientific discussion below (see <a href="#app1-molecules-25-04821">Appendix A</a> for methodology), we chose to include only peer-reviewed articles. In addition, we emphasize in this review cannabis drugs that have gone through legislation processes and registration as approved cannabis-related drugs. We use this list of drugs and scientific discussion to unveil the challenges and milestones that led us to the current situation in this arena, and then we further use this platform to draw outlines for future endeavors in this challenging field.</p> </div> <div class="1.2.basiccannabischemotaxonomy" title="sec"> <div class="title" tagx="title" title="title">
1.2. Basic Cannabis Chemotaxonomy</div> <p>To date, only a few cannabis-based pharmaceutical grade medicines have been developed and marketed. A review of the market reveals that registered cannabis-based drugs follow the common, rather dated, dichotomous chemo-variation approach to <i>Cannabis sativa</i>, where only the relative contents of Î"9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are considered [<a href="#B1-molecules-25-04821">1</a>]. Under this rather simplistic chemotaxonomy, cannabis strains are divided into three main chemovars on the basis of the relative amounts of the two predominant phytocannabinoids (i.e., cannabinoids produced by the plant). These include chemovar I with high levels of THC (THC &amp;gt;50% of total phytocannabinoid content), the intermediate chemovar II strains with equal relative amounts of THC and CBD, and chemovar III strains producing CBD as the dominant phytocannabinoid [<a href="#B1-molecules-25-04821">1</a>]. The basic cannabis chemotaxonomy gave grounds to the first drugs that were FDA-registered, as discussed below.</p> </div> <div class="1.3.briefintroductiontotheendocannabinoidsystem" title="sec"> <div class="title" tagx="title" title="title">
1.3. Brief Introduction to the Endocannabinoid System</div> <p>The endocannabinoid system includes the cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2), their endogenous endocannabinoids ligands (<i>N</i>-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG), and the endocannabinoid metabolism enzymes [<a href="#B2-molecules-25-04821">2</a>]. The latter include <i>sn</i>-1-specific diacylglycerol lipase-Î± (DGLÎ±), DGLÎ², <i>N</i>-acyl-phosphatidylethanolaminehydrolysing phospholipase D (NAPE-PLD), monoacylglycerol lipase (MAGL; also known as MGL), and fatty-acid amide hydrolase 1 (FAAH) [<a href="#B3-molecules-25-04821">3</a>]. The CB1 and CB2 receptors are G-protein-coupled receptors (GPCRs). CB1 is highly abundant in the brain, whereas CB2 is expressed mainly in immune cells but is also present at low levels in neuronal and non-neuronal brain cells [<a href="#B3-molecules-25-04821">3</a>]. CB1 and CB2 signaling involves alterations in Cyclic adenosine monophosphate (cAMP) levels, Extracellular regulated kinase 1/2 (ERK1/2) phosphorylation, and Î²-arrestin-2 recruitment [<a href="#B2-molecules-25-04821">2</a>]. They can also form heterodimers and lead to a biased agonistic response [<a href="#B4-molecules-25-04821">4</a>]. Alterations in concentrations of the endogenous endocannabinoid ligands, receptor expression or activity, or endocannabinoid metabolic enzyme activity have been found to be associated with varied pathological conditions [<a href="#B3-molecules-25-04821">3</a>].</p> </div> <div class="1.4.cannabinergiccompounds" title="sec"> <div class="title" tagx="title" title="title">
1.4. Cannabinergic Compounds</div> <p>Any molecule that modulates the endocannabinoid system, regardless of its chemical structure or pharmacological activity, is termed â€œcannabinergicâ€� [<a href="#B5-molecules-25-04821">5</a>]. The cannabinergic group of compounds includes CB1 or CB2 receptor ligands or blockers, substrates or inhibitors of fatty-acid amide hydrolase, and the endocannabinoid transporters. Studies of structureâ€"activity relationships between endocannabinoid receptors and many synthesized cannabinergic compounds (e.g., phytocannabinoid analogues and derivatives) have been performed, along with the determination of cannabinergic biological activities and pharmacokinetic properties [<a href="#B6-molecules-25-04821">6</a>,<a href="#B7-molecules-25-04821">7</a>,<a href="#B8-molecules-25-04821">8</a>]. Cannabinergic compounds are considered as targets for the development of novel medications, e.g., for pain management [<a href="#B7-molecules-25-04821">7</a>,<a href="#B9-molecules-25-04821">9</a>] or as anti-inflammatory therapeutics [<a href="#B10-molecules-25-04821">10</a>].</p> </div> </div> <div class="2.chronologyofcannabis-baseddrugdevelopment" title="sec"> <div class="title" tagx="title" title="title">
2. Chronology of Cannabis-Based Drug Development</div> <div class="2.1.drugsofonemolecule" title="sec"> <div class="title" tagx="title" title="title">
2.1. Drugs of One Molecule</div> <div class="2.1.1.cannabis-â€œinspiredâ€�drugs" title="sec"> <div class="title" tagx="title" title="title">
2.1.1. Cannabis-â€œInspiredâ€� Drugs</div> <p>Using a synthetic compound over the purified phytocannabinoid reflects the desire to brand a drug as a non-plant material, yet â€œinspiredâ€� by plant compounds. The first registered drug, Marinol<sup>Â®</sup>, contains high amounts of dronabinol, the synthetic equivalent of THC (<a href="#molecules-25-04821-t001">Table 1</a>). Marinol was registered and clinically tested for appetite stimulation and as an antiemetic. The antiemetic efficacy of Marinol was greatest in patients receiving cytotoxic therapy for Hodgkinâ€™s and non-Hodgkinâ€™s lymphomas. </p> </div> <div class="2.1.2.cannabis-deriveddrugs" title="sec"> <div class="title" tagx="title" title="title">
2.1.2. Cannabis-Derived Drugs</div> <p>The second drug registered, Epidiolex<sup>Â®</sup>, contains high amounts of plant-derived CBD (<a href="#molecules-25-04821-t001">Table 1</a>). Epidiolex, in development since 2002, was the first cannabis-derived drug approved by the United States US Food and Drug Administration (FDA) in 2018. The FDA granted approval of Epidiolex for the treatment of two rare and severe types of epilepsyâ€"Dravet syndrome and Lennoxâ€"Gastaut [<a href="#B11-molecules-25-04821">11</a>,<a href="#B12-molecules-25-04821">12</a>]. Other single-molecule drugs, inspired by or based on cannabis, were approved for the treatment of different medical conditions including cancer-related pain relief, appetite stimulation, and nausea and vomiting associated with cancer chemotherapy (<a href="#molecules-25-04821-t001">Table 1</a>). Recently, the FDA approved Epidiolex for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients 1 year of age and older [<a href="#B13-molecules-25-04821">13</a>]. Pure CBD has been shown in multiple preclinical and clinical studies to benefit Alzheimerâ€™s disease (AD) and multiple sclerosis (MS) patients. CBD was also shown in preclinical and clinical studies to have antiepileptic activity and was suggested to benefit Parkinsonâ€™s disease (PD) patients. However, more data are needed on the benefits of CBD activity for AD, MS, and PD patients [<a href="#B14-molecules-25-04821">14</a>]. It should be noted that CBD usage carries some adverse side effects. CBD use in animal models led to developmental toxicity, whereas, in human models, CBD use was associated with several adverse effects including diarrhea, fatigue, vomiting, somnolence, and certain drugâ€"drug interactions (detailed below) [<a href="#B15-molecules-25-04821">15</a>]. CBD toxicity and adverse effects should be stressed in light of the various marketing campaigns and anecdotal reports on the beneficial effects of CBD on multiple medical conditions, as well as the unregulated and ready availability of CBD products in some part of the world.</p> </div> </div> <div class="2.2.drugsofcombinatoricformulations" title="sec"> <div class="title" tagx="title" title="title">
2.2. Drugs of Combinatoric Formulations</div> <p>Sativex, a GW Pharmaceuticals drug designated for pain relief with relative equal amounts of both THC and CBD and some terpenes (<a href="#molecules-25-04821-t001">Table 1</a>), marked the updated notion of the power of plant-derived drugs based on the synergistic effect of different components. Sativex was targeted for the treatment of moderate to severe spasticity related with multiple sclerosis (MS). This is specifically in patients who have not responded sufficiently to other anti-spasticity medication. The results of a pivotal phase 3 trial suggested a successful Sativex therapy for this indication [<a href="#B22-molecules-25-04821">22</a>]. In addition, Sativex was shown to be effective for the treatment of other medical conditions. For example, treatment with Sativex was demonstrated to markedly improve the frequency and severity of motor and vocal tics post treatment in treatment-resistant Tourette syndrome patients [<a href="#B23-molecules-25-04821">23</a>]. Sativex is not yet approved by the FDA but it is registered for commercial distribution in Europe and Canada.</p> </div> </div> <div class="3.takingadvantageoftheâ€œentourageeffectâ€�" title="sec"> <div class="title" tagx="title" title="title">
3. Taking Advantage of the â€œEntourage Effectâ€�</div> <p>For many centuries, plants and plant extracts were used as phytomedicines for therapeutic treatments for a vast variety of symptoms and medical conditions [<a href="#B24-molecules-25-04821">24</a>]. Phytomedicines are based on the medical activity of active compounds present in plants. Moreover, in many cases, the biological effect of the whole-plant extract (solvent extraction, galenic preparation, or crude oil) was shown to have preferred activity over treatment with a single purified molecule. The enhancement of activity detected in phytomedicines was designated as the â€œentourageâ€� effect [<a href="#B25-molecules-25-04821">25</a>]. As detailed above, the idea behind drug development based on phytomedicines, like that of Marinol of GW pharmaceuticals, was to obtain the most abundant active compounds present in cannabis inflorescence and to mimic their activity using purified compounds administered in known dosages. However, different components present in plant extracts often promote the activity of the lead active compound(s) [<a href="#B26-molecules-25-04821">26</a>]. Hence, the ability of the â€œentourageâ€� effect to enhance medical activity should be examined.</p> <p>One major difficulty with evaluating the entourage effect of traditional medicines is that the underlying mechanism of action is unresolved. In fact, traditional medicines in general and phytomedicines in particular assume this â€œentourageâ€� as a concept or philosophy of therapy and, in many cases, strive to achieve it using a single-plant extract or some mixture of multiple plants. Some of the effects of compounds present in a given herbal preparation may be enhanced due to the cumulative activity of its constituents. In many other cases, the enhancement of activity by the combination of compounds may be at a synergistic level, as paired combinations of compounds exert effects that are more than the sum of their separate effects [<a href="#B27-molecules-25-04821">27</a>]. Synergy may be based on enhanced bioavailability and ease of transport of active compounds across barriers, such as cell or organelle membranes, or enhanced protection of an active molecule from degradation by enzymes [<a href="#B28-molecules-25-04821">28</a>]. Synergy may also result from the activation of more than one signaling pathway in the host cells, leading to an increased response [<a href="#B29-molecules-25-04821">29</a>].</p> <p>The â€œentourage effectâ€� as the enhanced activity of combinations of phytocannabinoids was first recognized by Mechoulam and Ben-Shabat [<a href="#B30-molecules-25-04821">30</a>]. We suggested that the â€œentourage effectâ€� was one of the main motivations and considerations in the domestication of cannabis [<a href="#B31-molecules-25-04821">31</a>]. Synergy in cannabis was recently demonstrated between phytocannabinoids [<a href="#B32-molecules-25-04821">32</a>,<a href="#B33-molecules-25-04821">33</a>] and further between phytocannabinoids and terpenes [<a href="#B34-molecules-25-04821">34</a>]. Moreover, insight into the synergy between cannabis compounds was provided at the levels of both chemical composition and respective biological activity [<a href="#B33-molecules-25-04821">33</a>,<a href="#B35-molecules-25-04821">35</a>]. The identified synergistic interactions between cannabis molecules might be the â€œentourage effectâ€� reported for cannabis preparations, as synergistic effects activate new biological pathways not activated by the components in isolation [<a href="#B33-molecules-25-04821">33</a>,<a href="#B35-molecules-25-04821">35</a>]. Importantly, herbal preparations of cannabis, cannabis varieties for use in medical preparations, and guidelines for prescribing doctors including physicianâ€™s recommendations, dosages, and titration strategies were recently reviewed in [<a href="#B36-molecules-25-04821">36</a>]. However, the incomplete understanding (for now) of the mechanism behind this â€œentourage effectâ€� in cannabis preparations makes it difficult to follow regular drug development and approval procedures (discussed below).</p> <p>Therefore, we suggest that the selection of combinations of highly active plant ingredients (APIs) from cannabis may open up new opportunities for drug development to treat various medical conditions [<a href="#B31-molecules-25-04821">31</a>]. Identifying the APIs and their specific compositions within a plant extract, followed by the manufacture of a pure and quantifiable compositions, may lead to pharmaceutical drugs inspired by or based on only the beneficial compounds in cannabis for a certain medical condition. Importantly, these might be targeted to specific mechanisms involved with different diseases [<a href="#B31-molecules-25-04821">31</a>,<a href="#B33-molecules-25-04821">33</a>,<a href="#B37-molecules-25-04821">37</a>].</p> </div> <div class="4.otherâ€œentourageâ€�considerations" title="sec"> <div class="title" tagx="title" title="title">
4. Other â€œEntourageâ€� Considerations</div> <div class="4.1.theâ€œparasitageeffectâ€�" title="sec"> <div class="title" tagx="title" title="title">
4.1. The â€œParasitage Effectâ€�</div> <p>While the overwhelming richness of compounds in cannabis strains can enhance activity, they can also depress activity. In addition to the APIs for the treatment of a given condition, whole extracts (solvent extraction, galenic preparation, or crude oil) also contain other compounds which do not contribute to the desired biological or clinical effect. Moreover, in cases where activity is improved by selecting the most active fractions and eliminating parts of the whole extract, there is a general implication that there might also be negative molecular interactions. Indeed, it was found that the removal of antagonistic or nonactive compounds lowered the required concentrations of APIs [<a href="#B33-molecules-25-04821">33</a>]. We call this phenomenon the â€œparasitage effectâ€�; in physics, the term â€œparasitageâ€� (<i>French</i>) describes destructive interference resulting from the interaction of coherent waves (for example) coming from the same source [<a href="#B38-molecules-25-04821">38</a>]. We use this term here to describe the contra-â€œentourage effectâ€�, a phenomenon in which certain coproduced compounds interfere with each other to diminish a chemo-biologic effect, instead of correlating to enhance it.</p> <p>The â€œparasitage effectâ€� of negative molecular interactions might result from the blockage of API-activated pathways. Cannabinoids target multiple receptors (e.g., CB1, CB2, transient receptor potential vanilloid receptor 1 (TRPV1)) [<a href="#B39-molecules-25-04821">39</a>]. Hence, antagonistic interference with API receptor binding might also provide evidence for the existence of the parasitage effect. Yet, specific negative interactions between cannabis compounds should still be demonstrated and the mechanism explored.</p> </div> <div class="4.2.interactionbetweenendocannabinoidsandcannabinoids(syntheticorplant-derived)" title="sec"> <div class="title" tagx="title" title="title">
4.2. Interaction between Endocannabinoids and Cannabinoids (Synthetic or Plant-Derived)</div> <p>Some of the effects of phytocannabinoids involve modulation (activation/inhibition) of receptors and enzymes associated with the endocannabinoid system, which may suggest that at least part of the phytocannabinoid mode of action involves modulation of endocannabinoid activity [<a href="#B40-molecules-25-04821">40</a>,<a href="#B41-molecules-25-04821">41</a>]. For example, THC and its propyl synthetic analogue tetrahydrocannabivarin (THCV) are capable of binding with high affinity to CB1 and CB2 receptors [<a href="#B39-molecules-25-04821">39</a>]. In another example, THC and non-THC phytocannabinoids activate and desensitize human heat-sensitive TRP channels of vanilloid type-1 (TRPV1). Anandamide is an endogenous agonist of TRPV1 [<a href="#B40-molecules-25-04821">40</a>]. Since both endocannabinoids and phytocannabinoids activate the same receptor (TRPV1 in this case), phytocannabinoids may share activity exhibited by endocannabinoids acting via the endocannabinoid receptors [<a href="#B40-molecules-25-04821">40</a>]. Phytocannabinoids may also alter endocannabinoid levels; CBD was shown to stimulate TRPV1 and, thus, inhibit anandamide uptake, leading to increased levels of endogenous AEA in an in vitro study [<a href="#B42-molecules-25-04821">42</a>]. Phytocannabinoids were also shown to alter the activity of endocannabinoid enzymes; CBD in vivo treatment of the nude mouse xenograft model increased the activity of FAAH while decreasing anandamide content in tumor samples [<a href="#B43-molecules-25-04821">43</a>]. However, the relevance of the interactions between phytocannabinoids and the endocannabinoid system to clinical uses needs to be further studied. Regardless, the effect on the endocannabinoid system by cannabis-inspired or cannabis-based drugs formulated from one or multiple molecules should be considered.</p> </div> <div class="4.3.degradationandlossofactivation" title="sec"> <div class="title" tagx="title" title="title">
4.3. Degradation and Loss of Activation</div> <p>Natural ratios of phytocannabinoids have been used as the basis for drug development. Several ratios found in plants display higher activity than others [<a href="#B34-molecules-25-04821">34</a>]. When these phytocannabinoid ratios are altered, there is no enhancement of activity [<a href="#B44-molecules-25-04821">44</a>]. Additionally, certain phytocannabinoids are more susceptive to degradation and more volatile than others [<a href="#B45-molecules-25-04821">45</a>,<a href="#B46-molecules-25-04821">46</a>]. Good manufacturing practices (GMP) should take into consideration the degradation of phytocannabinoids in medical-grade products to maintain the effective natural or established ratios and avoid substantial reduction in activity.</p> </div> </div> <div class="5.drugâ€" title="sec"> <div class="title" tagx="title" title="title">
5. Drugâ€"Drug Interactions</div> <p>A change in a drugâ€™s effect on the body when taken together with other drugs, such as common drugâ€"drug interactions (DDIs), should be considered more broadly since DDI may modulate efficacy versus toxicity. Most commonly, DDI results in adverse drug events, which may be caused from changes in pharmaceutical, pharmacokinetic, or pharmacodynamic properties. The interactions between plant-derived products and synthetic drugs (herein â€œdrugsâ€�) are based on the same pharmacokinetic and pharmacodynamic principles as DDIs. The studies of drugâ€"drug, foodâ€"drug, and particularly plant-derived drugâ€"drug interactions and genetic factors affecting pharmacokinetics and pharmacodynamics are expected to improve drug safety and to enable personalized drug therapy. Attention is needed for interactions between plant-derived products and synthetic drugs (or naturally occurring chemicals) with a narrow therapeutic index (i.e., a narrow range of doses that confer effectivity without unacceptable adverse effects). However, to date, well-designed clinical studies evaluating herbal supplementâ€"drug interactions are limited; however, case reports are available [<a href="#B47-molecules-25-04821">47</a>,<a href="#B48-molecules-25-04821">48</a>,<a href="#B49-molecules-25-04821">49</a>].</p> <p>On the other hand, there are numerous in vitro and in vivo studies indicating that phytocannabinoid metabolism is mostly performed by the cytochrome P450 (CYP) isoenzymes. For example, CBD is metabolized by CYP 3A4 and 2C19 and to a lesser extent by CYP 2c8, 2C9, 1A2, 2C8, 2B6, and 2E1 [<a href="#B50-molecules-25-04821">50</a>,<a href="#B51-molecules-25-04821">51</a>]. This metabolism via CYP enzymes may inhibit or enhance their activity and, thus, affect the metabolism of various drugs, resulting in different DDI outcomes. In one case study, a threefold increase in tacrolimus levels was detected following the addition of CBD due to CYP3A4/5 inhibition. CBD also inhibits CYP2C19, and a threefold increase in levels of the active metabolite of clobazam has been reported [<a href="#B52-molecules-25-04821">52</a>]. Interactions with other drugs metabolized by these isoenzymes should be anticipated.</p> <p>In addition, CBD is a potent inhibitor of CYP2D6 [<a href="#B53-molecules-25-04821">53</a>]. CYP2D6 metabolizes many antidepressants; thus, CBD may increase serum concentrations of selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, antipsychotics, beta blockers, and opioids (including codeine and oxycodone) [<a href="#B54-molecules-25-04821">54</a>]. In contrast, any drug presenting an inhibiting or inducing effect on one of these enzymes may change CBD pharmacodynamics and, thus, affect CBD levels [<a href="#B55-molecules-25-04821">55</a>]. These effects should be considered in the riskâ€"benefit assessment of CBD therapy, and patients and consumers should be made aware of the potential safety hazards of CBD use. Some CYP isoform activity is crucial for the endocannabinoid system. Cardiac CYP2J2 for example, which is inhibited by several phytocannabinoids, results in reduced metabolism of endogenous cardioprotective cannabinoids, such as anandamide [<a href="#B56-molecules-25-04821">56</a>].</p> <p>Overall, although further research on DDIs of CBD is needed, CBD may have serious interactions with drugs. It can affect the levels of other drugs, while its own level can be increased or decreased by other medications, and additive effects of CBD can occur with other drugs (e.g., in the case of painkillers).</p> </div> <div class="6.registrationdrugs:onemoleculeorcombinatoricformulations" title="sec"> <div class="title" tagx="title" title="title">
6. Registration Drugs: One Molecule or Combinatoric Formulations</div> <p>There is a significant interest in the development of therapies and other consumer products derived from cannabis and its components, including CBD. Registering one, a few, or multiple molecules as drugs is a challenging task. Despite the synergistic effect of plant extracts over single compounds, traditional medicines based on whole plants, herbal extracts, or mixtures cannot be recognized as certified drugs as they are non-registerable [<a href="#B36-molecules-25-04821">36</a>,<a href="#B57-molecules-25-04821">57</a>]. Registerable drugs are based on known amounts of pure compounds, which can be synthesized and recombined and, thus, registered as formulated medicines. Chemical compositions of plant extracts are highly complex with up to hundreds of different components. Thus, their exact combination is not reproducible by plant growth according to the good manufacturing practices (GMP). Therefore, identifying active compounds in order to either purify or synthesize the determined active ingredients into effective and reproducible drugs is the focus of pharmaceutical companies.</p> <p>Obviously, patients should have confidence in the drugâ€™s uniformity, strength, and consistent delivery that support appropriate dosing needed to treat patients with complex and serious conditions. This also applies to â€œcombination productsâ€�. To that purpose, the FDA issued guidance for GMP requirements for combination products [<a href="#B58-molecules-25-04821">58</a>], to codify the availability and quality of drugs, biologics, devices, and combination products that consistently meet applicable requirements and specifications both as combination products or as single drugs. Reasons for the rejection of combination products might include pharmacokinetics and/or pharmacodynamic interactions between the combined constituents, the effects of additional manufacturing steps, or other differences arising from combinations.</p> <p>An FDA guideline was also issued on the regulation of cannabis and cannabis-derived products, including CBD. The FDA stated that it recognizes the potential opportunities that cannabis or cannabis-derived compounds may offer and acknowledges the significance of these possibilities. However, it is also aware of some companies that are marketing cannabis-derived compounds in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;amp;C Act), and this marketing may put the health and safety of consumers at risk [<a href="#B59-molecules-25-04821">59</a>].</p> <p>The drug review and approval process generally contains several defined steps. <a href="#molecules-25-04821-t002">Table 2</a> provides a brief summary of the Canadian Drug Review and Approval Process in accordance with the Food and Drugs Act (FDA), the Food and Drug Regulations (FDR), the related policies, and Health Canada guidelines, which are similar in most countries [<a href="#B60-molecules-25-04821">60</a>]. Canada is the first G20 country to legalize cannabis on a national scale, for both recreational and medicinal purposes. Consequently, several biotech and big pharmaceutical companies have officially entered the Canadian cannabis industry to facilitate cannabis legalization and regulation in other countries.</p> </div> <div class="conclusions" title="conclusions"> <div class="title" tagx="title" title="title">
7. Conclusions and Future Prospects</div> <p>Cannabis-based therapy is a powerful and promising tool as it takes advantage of an existing receptor system to affect multiple body systems and biological processes. However, as this sensitive and balanced endocannabinoids system serves other endogenous molecules and is also associated with drug metabolism, cannabis-based therapy must be carefully examined and applied.</p> <p>As illustrated in <a href="#molecules-25-04821-f001">Figure 1</a>, cannabis-inspired drugs may be developed as synthetic cannabinoids or their derivatives. Cannabinergic drugs may also be developed to specifically attenuate components of the endocannabinoid system (e.g., endocannabinoid receptors). Cannabis-based drugs may be composed of one phytomolecule or as a combination of APIs from the plant. The activity of API combinations may be enhanced by taking advantage of the â€œentourageâ€� and avoiding the â€œparasitageâ€� effects. In any case, interaction(s) between endocannabinoids and cannabinoids (synthetic or plant-derived) or cannabinergic compounds must be examined, and steps for drug review should be taken and approval processes be followed, taking into consideration the need to register and approve drugs of combinatoric formulations.</p> <p>As for the future, we appreciate the aspects involved in cannabis-based drug development, such as complex entourage effects and terpene considerations [<a href="#B33-molecules-25-04821">33</a>,<a href="#B34-molecules-25-04821">34</a>,<a href="#B35-molecules-25-04821">35</a>,<a href="#B36-molecules-25-04821">36</a>,<a href="#B37-molecules-25-04821">37</a>]. We also acknowledge the current difficulties of the pharma industry to include natural preparations, as discussed above. However, significant efforts are ongoing in different research laboratories toward revealing the mechanisms and modes of action of other chemical constituents chaperoning the various cannabinoid(s) in whole extracts, such as terpenes and flavonoids. These attempts currently follow indications proved only at the cellular/tissue level. We believe that, as these attempts will bear fruit and the mode of action of the cannabinoids chaperons will be revealed, the pharmaceutical industry will follow these leads for the development of new generations of cannabis-based pharmaceutical products.</p> </div> </div> <div class="back" title="back"> <div class="ack" title="ack"> <div class="title" tagx="title" title="title">
Acknowledgments</div> <p>We thank Zach Dunseth for English editing.</p> </div> <div class="fn-group" title="fn-group"> <div class="fn-type-" title=""> <p><b>Publisherâ€™s Note:</b> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p> </div> </div> <div class="title" tagx="title" title="title">
Funding</div> <p>This research received no external funding.</p> <div class="title" tagx="title" title="title">
Conflicts of Interest</div> <p>The authors declare no conflict of interest.</p> <div class="app-group" title="app-group"> <div class="app" title="app"> <div class="title" tagx="title" title="title">
Appendix A</div> <p>Methodology: To reflect the challenging processes of translation of the accumulating knowledge regarding the active compounds and their mode of action into modern, registered, pharmaceutical drugs, a literature search was done using the following terms: â€œcannabisâ€�, â€œ<i>Cannabis sativa</i>â€�, â€œ<i>C. sativa</i>â€�, â€œcannabinoidsâ€�, â€œterpenesâ€�, â€œmedical useâ€�, â€œherbal preparationsâ€�, â€œhempâ€�, â€œoilâ€�, â€œtherapyâ€�, â€œadverse effectsâ€�, â€œcannabis chemotaxonomyâ€�, â€œendocannabinoidâ€�, â€œcannabinergic compoundsâ€�, â€œentourage effectâ€�, â€œparasitageâ€�, â€œdegradationâ€�, â€œdrugâ€"drug interactionsâ€�, and â€œdrug registrationâ€�. The search was conducted on general and multidisciplinary research databases for peer-reviewed scientific manuscripts, such as PubMed, Google Scholar, Scopus, and Web of Science. Furthermore, a web search was carried out using the following websites for a non-exhaustive list of examples of medicines: US FDA, Canadaâ€™s Food and Drugs Act, and The Drug Review and Approval Processes in Canada (updated to October 2020).</p> </div> </div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="B1-molecules-25-04821" /><span class="label" tagx="label" title="label">1.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Small</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Beckstead</span><span class="given-names" tagx="given-names" title="given-names">H.D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cannabinoid Phenotypes in Cannabis sativa</span><span class="source" tagx="source" title="source">Nat. Cell Biol.</span><span class="year" tagx="year" title="year">1973</span><span class="volume" tagx="volume" title="volume">245</span><span class="fpage" tagx="fpage" title="fpage">147</span><span class="lpage" tagx="lpage" title="lpage">148</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/245147a0">10.1038/245147a0</a></span></span></li> <li tag="ref"><a name="B2-molecules-25-04821" /><span class="label" tagx="label" title="label">2.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Howlett</span><span class="given-names" tagx="given-names" title="given-names">A.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abood</span><span class="given-names" tagx="given-names" title="given-names">M.E.</span></span></span><span class="mixed-article-title" title="mixed-article-title">CB 1 and CB 2 Receptor Pharmacology</span><span class="source" tagx="source" title="source">Studies in Surface Science and Catalysis</span><span class="publisher-name" tagx="publisher-name" title="publisher-name">Elsevier BV</span><span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">Amsterdam, The Netherlands</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">Volume 80</span><span class="fpage" tagx="fpage" title="fpage">169</span><span class="lpage" tagx="lpage" title="lpage">206</span></span></li> <li tag="ref"><a name="B3-molecules-25-04821" /><span class="label" tagx="label" title="label">3.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Di Marzo</span><span class="given-names" tagx="given-names" title="given-names">V.</span></span></span><span class="mixed-article-title" title="mixed-article-title">New approaches and challenges to targeting the endocannabinoid system</span><span class="source" tagx="source" title="source">Nat. Rev. Drug Discov.</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">17</span><span class="fpage" tagx="fpage" title="fpage">623</span><span class="lpage" tagx="lpage" title="lpage">639</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/nrd.2018.115">10.1038/nrd.2018.115</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30116049">30116049</a></span></span></li> <li tag="ref"><a name="B4-molecules-25-04821" /><span class="label" tagx="label" title="label">4.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Navarro</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Varani</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lillo</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vincenzi</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rivas-Santisteban</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">RaÃ¯ch</span><span class="given-names" tagx="given-names" title="given-names">I.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Reyes-Resina</span><span class="given-names" tagx="given-names" title="given-names">I.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ferreiro-Vera</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Borea</span><span class="given-names" tagx="given-names" title="given-names">P.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Medina</span><span class="given-names" tagx="given-names" title="given-names">V.S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Pharmacological data of cannabidiol-and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1/CB2 heteromer receptors</span><span class="source" tagx="source" title="source">Pharmacol. Res.</span><span class="year" tagx="year" title="year">2020</span><span class="volume" tagx="volume" title="volume">159</span><span class="fpage" tagx="fpage" title="fpage">104940</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.phrs.2020.104940">10.1016/j.phrs.2020.104940</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32470563">32470563</a></span></span></li> <li tag="ref"><a name="B5-molecules-25-04821" /><span class="label" tagx="label" title="label">5.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Goutopoulos</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Makriyannis</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">From cannabis to cannabinergics: New therapeutic opportunities</span><span class="source" tagx="source" title="source">Pharmacol. Ther.</span><span class="year" tagx="year" title="year">2002</span><span class="volume" tagx="volume" title="volume">95</span><span class="fpage" tagx="fpage" title="fpage">103</span><span class="lpage" tagx="lpage" title="lpage">117</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/S0163-7258(02)00250-4">10.1016/S0163-7258(02)00250-4</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12182958">12182958</a></span></span></li> <li tag="ref"><a name="B6-molecules-25-04821" /><span class="label" tagx="label" title="label">6.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lu</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Meng</span><span class="given-names" tagx="given-names" title="given-names">Z.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Thakur</span><span class="given-names" tagx="given-names" title="given-names">G.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fan</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Steed</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tartal</span><span class="given-names" tagx="given-names" title="given-names">C.L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hurst</span><span class="given-names" tagx="given-names" title="given-names">D.P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Reggio</span><span class="given-names" tagx="given-names" title="given-names">P.H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Deschamps</span><span class="given-names" tagx="given-names" title="given-names">J.R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Parrish</span><span class="given-names" tagx="given-names" title="given-names">D.A.</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Adamantyl Cannabinoids: A Novel Class of Cannabinergic Ligands</span><span class="source" tagx="source" title="source">J. Med. Chem.</span><span class="year" tagx="year" title="year">2005</span><span class="volume" tagx="volume" title="volume">48</span><span class="fpage" tagx="fpage" title="fpage">4576</span><span class="lpage" tagx="lpage" title="lpage">4585</span><span class="pub-id"><a href="https://dx.doi.org/10.1021/jm058175c">10.1021/jm058175c</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15999995">15999995</a></span></span></li> <li tag="ref"><a name="B7-molecules-25-04821" /><span class="label" tagx="label" title="label">7.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Silva</span><span class="given-names" tagx="given-names" title="given-names">N.R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gomes</span><span class="given-names" tagx="given-names" title="given-names">F.V.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fonseca</span><span class="given-names" tagx="given-names" title="given-names">M.D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mechoulam</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Breuer</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cunha</span><span class="given-names" tagx="given-names" title="given-names">T.M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">GuimarÃ£es</span><span class="given-names" tagx="given-names" title="given-names">F.S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative</span><span class="source" tagx="source" title="source">Prog. Neuro Psychopharmacol. Biol. Psychiatry</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">79</span><span class="fpage" tagx="fpage" title="fpage">369</span><span class="lpage" tagx="lpage" title="lpage">377</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.pnpbp.2017.07.012">10.1016/j.pnpbp.2017.07.012</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28720466">28720466</a></span></span></li> <li tag="ref"><a name="B8-molecules-25-04821" /><span class="label" tagx="label" title="label">8.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kulkarni</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nikas</span><span class="given-names" tagx="given-names" title="given-names">S.P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sharma</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jiang</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Paronis</span><span class="given-names" tagx="given-names" title="given-names">C.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Leonard</span><span class="given-names" tagx="given-names" title="given-names">M.Z.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">B.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Honrao</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mallipeddi</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Raghav</span><span class="given-names" tagx="given-names" title="given-names">J.G.</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues</span><span class="source" tagx="source" title="source">J. Med. Chem.</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">59</span><span class="fpage" tagx="fpage" title="fpage">6903</span><span class="lpage" tagx="lpage" title="lpage">6919</span><span class="pub-id"><a href="https://dx.doi.org/10.1021/acs.jmedchem.6b00717">10.1021/acs.jmedchem.6b00717</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27367336">27367336</a></span></span></li> <li tag="ref"><a name="B9-molecules-25-04821" /><span class="label" tagx="label" title="label">9.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aggarwal</span><span class="given-names" tagx="given-names" title="given-names">S.K.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cannabinergic Pain Medicine</span><span class="source" tagx="source" title="source">Clin. J. Pain</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">29</span><span class="fpage" tagx="fpage" title="fpage">162</span><span class="lpage" tagx="lpage" title="lpage">171</span><span class="pub-id"><a href="https://dx.doi.org/10.1097/AJP.0b013e31824c5e4c">10.1097/AJP.0b013e31824c5e4c</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22367503">22367503</a></span></span></li> <li tag="ref"><a name="B10-molecules-25-04821" /><span class="label" tagx="label" title="label">10.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lu</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vemuri</span><span class="given-names" tagx="given-names" title="given-names">V.K.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Duclos</span><span class="given-names" tagx="given-names" title="given-names">R.I.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Makriyannis</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The Cannabinergic System as a Target for Anti-inflammatory Therapies</span><span class="source" tagx="source" title="source">Curr. Top. Med. Chem.</span><span class="year" tagx="year" title="year">2006</span><span class="volume" tagx="volume" title="volume">6</span><span class="fpage" tagx="fpage" title="fpage">1401</span><span class="lpage" tagx="lpage" title="lpage">1426</span><span class="pub-id"><a href="https://dx.doi.org/10.2174/15680266106061401">10.2174/15680266106061401</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16918457">16918457</a></span></span></li> <li tag="ref"><a name="B11-molecules-25-04821" /><span class="label" tagx="label" title="label">11.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Felberbaum</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy</span><span class="comment">Available online: <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms">https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms</a></span><span class="date-in-citation" tagx="date-in-citation" title="date-in-citation">(accessed on 25 June 2018)</span></span></li> <li tag="ref"><a name="B12-molecules-25-04821" /><span class="label" tagx="label" title="label">12.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sekar</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pack</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Epidiolex as adjunct therapy for treatment of refractory epilepsy: A comprehensive review with a focus on adverse effects</span><span class="source" tagx="source" title="source">F1000Res</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">8</span><span class="fpage" tagx="fpage" title="fpage">234</span><span class="pub-id"><a href="https://dx.doi.org/10.12688/f1000research.16515.1">10.12688/f1000research.16515.1</a></span></span></li> <li tag="ref"><a name="B13-molecules-25-04821" /><span class="label" tagx="label" title="label">13.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Oâ€™Keefe</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span></span><span class="mixed-article-title" title="mixed-article-title">FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease</span><span class="comment">Available online: <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-drug-containing-active-ingredient-derived-cannabis-treat-seizures-rare">https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-drug-containing-active-ingredient-derived-cannabis-treat-seizures-rare</a></span><span class="date-in-citation" tagx="date-in-citation" title="date-in-citation">(accessed on 31 July 2020)</span></span></li> <li tag="ref"><a name="B14-molecules-25-04821" /><span class="label" tagx="label" title="label">14.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mannucci</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Navarra</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Calapai</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Spagnolo</span><span class="given-names" tagx="given-names" title="given-names">E.V.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">BusardÃ²</span><span class="given-names" tagx="given-names" title="given-names">F.P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cas</span><span class="given-names" tagx="given-names" title="given-names">R.D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ippolito</span><span class="given-names" tagx="given-names" title="given-names">F.M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Calapai</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Neurological aspects of medical use of cannabidiol</span><span class="source" tagx="source" title="source">CNS Neurol. Disord. Drug Targets</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">16</span><span class="fpage" tagx="fpage" title="fpage">541</span><span class="lpage" tagx="lpage" title="lpage">553</span><span class="pub-id"><a href="https://dx.doi.org/10.2174/1871527316666170413114210">10.2174/1871527316666170413114210</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28412918">28412918</a></span></span></li> <li tag="ref"><a name="B15-molecules-25-04821" /><span class="label" tagx="label" title="label">15.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Huestis</span><span class="given-names" tagx="given-names" title="given-names">M.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Solimini</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pichini</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pacifici</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Carlier</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">BusardÃ²</span><span class="given-names" tagx="given-names" title="given-names">F.P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cannabidiol adverse effects and toxicity</span><span class="source" tagx="source" title="source">Curr. Neuropharmacol.</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">17</span><span class="fpage" tagx="fpage" title="fpage">974</span><span class="lpage" tagx="lpage" title="lpage">989</span><span class="pub-id"><a href="https://dx.doi.org/10.2174/1570159X17666190603171901">10.2174/1570159X17666190603171901</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31161980">31161980</a></span></span></li> <li tag="ref"><a name="B16-molecules-25-04821" /><span class="label" tagx="label" title="label">16.</span><span class="element-citation'"><span class="mixed-article-title" title="mixed-article-title">Marinol</span><span class="comment">Available online: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018651s021lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018651s021lbl.pdf</a></span><span class="date-in-citation" tagx="date-in-citation" title="date-in-citation">(accessed on 15 September 2004)</span></span></li> <li tag="ref"><a name="B17-molecules-25-04821" /><span class="label" tagx="label" title="label">17.</span><span class="element-citation'"><span class="mixed-article-title" title="mixed-article-title">EPIDIOLEXÂ® (cannabidiol) oral solution, CX pending DEA scheduling action</span><span class="comment">Available online: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf</a></span><span class="date-in-citation" tagx="date-in-citation" title="date-in-citation">(accessed on 10 June 2018)</span></span></li> <li tag="ref"><a name="B18-molecules-25-04821" /><span class="label" tagx="label" title="label">18.</span><span class="element-citation'"><span class="mixed-article-title" title="mixed-article-title">SYNDROS (dronabinol) oral solution, CII</span><span class="comment">Available online: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205525s003lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205525s003lbl.pdf</a></span><span class="date-in-citation" tagx="date-in-citation" title="date-in-citation">(accessed on 15 May 2017)</span></span></li> <li tag="ref"><a name="B19-molecules-25-04821" /><span class="label" tagx="label" title="label">19.</span><span class="element-citation'"><span class="mixed-article-title" title="mixed-article-title">CESAMETâ"¢ (nabilone)</span><span class="comment">Available online: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf</a></span><span class="date-in-citation" tagx="date-in-citation" title="date-in-citation">(accessed on 20 May 2006)</span></span></li> <li tag="ref"><a name="B20-molecules-25-04821" /><span class="label" tagx="label" title="label">20.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Carvalho</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Phase 1 Trial of EB Cannabinol Cream Completes Treatment in Healthy Volunteers</span><span class="comment">Available online: <a href="https://epidermolysisbullosanews.com/2020/04/09/phase-1-trial-of-eb-cannabinol-cream-completes-treatment-in-healthy-volunteers">https://epidermolysisbullosanews.com/2020/04/09/phase-1-trial-of-eb-cannabinol-cream-completes-treatment-in-healthy-volunteers</a></span><span class="date-in-citation" tagx="date-in-citation" title="date-in-citation">(accessed on 9 April 2020)</span></span></li> <li tag="ref"><a name="B21-molecules-25-04821" /><span class="label" tagx="label" title="label">21.</span><span class="element-citation'"><span class="mixed-article-title" title="mixed-article-title">Sativex Oromucosal Spray</span><span class="comment">Available online: <a href="https://www.medicines.org.uk/emc/product/602/smpc">https://www.medicines.org.uk/emc/product/602/smpc</a></span><span class="date-in-citation" tagx="date-in-citation" title="date-in-citation">(accessed on 27 May 2020)</span></span></li> <li tag="ref"><a name="B22-molecules-25-04821" /><span class="label" tagx="label" title="label">22.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Keating</span><span class="given-names" tagx="given-names" title="given-names">G.M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Delta-9-tetrahydrocannabinol/cannabidiol oromucosal spray (Sativex<sup>Â®</sup>): A review in multiple sclerosis-related spasticity</span><span class="source" tagx="source" title="source">Drugs</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">77</span><span class="fpage" tagx="fpage" title="fpage">563</span><span class="lpage" tagx="lpage" title="lpage">574</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s40265-017-0720-6">10.1007/s40265-017-0720-6</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28293911">28293911</a></span></span></li> <li tag="ref"><a name="B23-molecules-25-04821" /><span class="label" tagx="label" title="label">23.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Trainor</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Evans</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bird</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Severe motor and vocal tics controlled with Sativex<sup>Â®</sup></span><span class="source" tagx="source" title="source">Australas Psychiatry</span><span class="year" tagx="year" title="year">2016</span><span class="volume" tagx="volume" title="volume">24</span><span class="fpage" tagx="fpage" title="fpage">541</span><span class="lpage" tagx="lpage" title="lpage">544</span><span class="pub-id"><a href="https://dx.doi.org/10.1177/1039856216663737">10.1177/1039856216663737</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27558217">27558217</a></span></span></li> <li tag="ref"><a name="B24-molecules-25-04821" /><span class="label" tagx="label" title="label">24.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pan</span><span class="given-names" tagx="given-names" title="given-names">S.Y.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Litscher</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gao</span><span class="given-names" tagx="given-names" title="given-names">S.H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhou</span><span class="given-names" tagx="given-names" title="given-names">S.F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yu</span><span class="given-names" tagx="given-names" title="given-names">Z.L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">H.Q.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">S.F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tang</span><span class="given-names" tagx="given-names" title="given-names">M.K.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sun</span><span class="given-names" tagx="given-names" title="given-names">J.N.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ko</span><span class="given-names" tagx="given-names" title="given-names">K.M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Historical perspective of traditional indigenous medical practices: The current renaissance and conservation of herbal resources</span><span class="source" tagx="source" title="source">Evid. Based Complement Alternat. Med.</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">2014</span><span class="fpage" tagx="fpage" title="fpage">1</span><span class="lpage" tagx="lpage" title="lpage">20</span><span class="pub-id"><a href="https://dx.doi.org/10.1155/2014/525340">10.1155/2014/525340</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24872833">24872833</a></span></span></li> <li tag="ref"><a name="B25-molecules-25-04821" /><span class="label" tagx="label" title="label">25.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ribeiro</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Whole organisms or pure compounds? Entourage effect versus drug specificity</span><span class="source" tagx="source" title="source">Plant Medicines, Healing and Psychedelic Science</span><span class="publisher-name" tagx="publisher-name" title="publisher-name">Springer Nature</span><span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">Cham, Switzerland</span><span class="year" tagx="year" title="year">2018</span><span class="fpage" tagx="fpage" title="fpage">133</span><span class="lpage" tagx="lpage" title="lpage">149</span></span></li> <li tag="ref"><a name="B26-molecules-25-04821" /><span class="label" tagx="label" title="label">26.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Williamson</span><span class="given-names" tagx="given-names" title="given-names">E.M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Synergy and other interactions in phytomedicines</span><span class="source" tagx="source" title="source">Phytomedicine</span><span class="year" tagx="year" title="year">2001</span><span class="volume" tagx="volume" title="volume">8</span><span class="fpage" tagx="fpage" title="fpage">401</span><span class="lpage" tagx="lpage" title="lpage">409</span><span class="pub-id"><a href="https://dx.doi.org/10.1078/0944-7113-00060">10.1078/0944-7113-00060</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11695885">11695885</a></span></span></li> <li tag="ref"><a name="B27-molecules-25-04821" /><span class="label" tagx="label" title="label">27.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Odds</span><span class="given-names" tagx="given-names" title="given-names">F.C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Synergy, antagonism, and what the chequerboard puts between them</span><span class="source" tagx="source" title="source">J. Antimicrob. Chemother.</span><span class="year" tagx="year" title="year">2003</span><span class="volume" tagx="volume" title="volume">52</span><span class="fpage" tagx="fpage" title="fpage">1</span><span class="pub-id"><a href="https://dx.doi.org/10.1093/jac/dkg301">10.1093/jac/dkg301</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12805255">12805255</a></span></span></li> <li tag="ref"><a name="B28-molecules-25-04821" /><span class="label" tagx="label" title="label">28.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gilbert</span><span class="given-names" tagx="given-names" title="given-names">B.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alves</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Synergy in plant medicines</span><span class="source" tagx="source" title="source">Curr. Med. Chem.</span><span class="year" tagx="year" title="year">2003</span><span class="volume" tagx="volume" title="volume">10</span><span class="fpage" tagx="fpage" title="fpage">13</span><span class="lpage" tagx="lpage" title="lpage">20</span><span class="pub-id"><a href="https://dx.doi.org/10.2174/0929867033368583">10.2174/0929867033368583</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12570718">12570718</a></span></span></li> <li tag="ref"><a name="B29-molecules-25-04821" /><span class="label" tagx="label" title="label">29.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guo</span><span class="given-names" tagx="given-names" title="given-names">X.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">X.-F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Signaling cross-talk between TGF-Î²/BMP and other pathways</span><span class="source" tagx="source" title="source">Cell Res.</span><span class="year" tagx="year" title="year">2009</span><span class="volume" tagx="volume" title="volume">19</span><span class="fpage" tagx="fpage" title="fpage">71</span><span class="lpage" tagx="lpage" title="lpage">88</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/cr.2008.302">10.1038/cr.2008.302</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19002158">19002158</a></span></span></li> <li tag="ref"><a name="B30-molecules-25-04821" /><span class="label" tagx="label" title="label">30.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mechoulam</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ben-Shabat</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: The ongoing story of cannabis</span><span class="source" tagx="source" title="source">Nat. Prod. Rep.</span><span class="year" tagx="year" title="year">1999</span><span class="volume" tagx="volume" title="volume">16</span><span class="fpage" tagx="fpage" title="fpage">131</span><span class="lpage" tagx="lpage" title="lpage">143</span><span class="pub-id"><a href="https://dx.doi.org/10.1039/a703973e">10.1039/a703973e</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10331283">10331283</a></span></span></li> <li tag="ref"><a name="B31-molecules-25-04821" /><span class="label" tagx="label" title="label">31.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Koltai</span><span class="given-names" tagx="given-names" title="given-names">H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Namdar</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cannabis Phytomolecule â€™Entourageâ€™: From Domestication to Medical Use</span><span class="source" tagx="source" title="source">Trends Plant Sci.</span><span class="year" tagx="year" title="year">2020</span><span class="volume" tagx="volume" title="volume">25</span><span class="fpage" tagx="fpage" title="fpage">976</span><span class="lpage" tagx="lpage" title="lpage">984</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.tplants.2020.04.007">10.1016/j.tplants.2020.04.007</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32417167">32417167</a></span></span></li> <li tag="ref"><a name="B32-molecules-25-04821" /><span class="label" tagx="label" title="label">32.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Berman</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Futoran</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lewitus</span><span class="given-names" tagx="given-names" title="given-names">G.M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mukha</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Benami</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shlomi</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Meiri</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis</span><span class="source" tagx="source" title="source">Sci. Rep.</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">8</span><span class="fpage" tagx="fpage" title="fpage">1</span><span class="lpage" tagx="lpage" title="lpage">15</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/s41598-018-32651-4">10.1038/s41598-018-32651-4</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29311619">29311619</a></span></span></li> <li tag="ref"><a name="B33-molecules-25-04821" /><span class="label" tagx="label" title="label">33.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mazuz</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tiroler</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Moyal</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hodak</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nadarajan</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vinayaka</span><span class="given-names" tagx="given-names" title="given-names">A.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gorovitz-Haris</span><span class="given-names" tagx="given-names" title="given-names">B.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lubin</span><span class="given-names" tagx="given-names" title="given-names">I.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Drori</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Drori</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synergistic cytotoxic activity of cannabinoids from <i>Cannabis sativa</i> against cutaneous T-cell lymphoma (CTCL) in-vitro and ex-vivo</span><span class="source" tagx="source" title="source">Oncotarget</span><span class="year" tagx="year" title="year">2020</span><span class="volume" tagx="volume" title="volume">11</span><span class="fpage" tagx="fpage" title="fpage">1141</span><span class="lpage" tagx="lpage" title="lpage">1156</span><span class="pub-id"><a href="https://dx.doi.org/10.18632/oncotarget.27528">10.18632/oncotarget.27528</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32284791">32284791</a></span></span></li> <li tag="ref"><a name="B34-molecules-25-04821" /><span class="label" tagx="label" title="label">34.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Namdar</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Voet</span><span class="given-names" tagx="given-names" title="given-names">H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ajjampura</span><span class="given-names" tagx="given-names" title="given-names">V.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nadarajan</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mayzlish-Gati</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mazuz</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shalev</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Koltai</span><span class="given-names" tagx="given-names" title="given-names">H.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Terpenoids and phytocannabinoids co-produced in Cannabis sativa strains show specific interaction for cell cytotoxic activity</span><span class="source" tagx="source" title="source">Molecules</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">24</span><span class="elocation-id" tagx="elocation-id" title="elocation-id">3031</span><span class="pub-id"><a href="https://dx.doi.org/10.3390/molecules24173031">10.3390/molecules24173031</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31438532">31438532</a></span></span></li> <li tag="ref"><a name="B35-molecules-25-04821" /><span class="label" tagx="label" title="label">35.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nallathambi</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mazuz</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ion</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Selvaraj</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Weininger</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fridlender</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ahmad</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sagee</span><span class="given-names" tagx="given-names" title="given-names">O.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kumari</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nemichenizer</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Anti-inflammatory activity in colon models is derived from Î´9-tetrahydrocannabinolic acid that interacts with additional compounds in cannabis extracts</span><span class="source" tagx="source" title="source">Cannabis Cannabinoid Res.</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">2</span><span class="fpage" tagx="fpage" title="fpage">167</span><span class="lpage" tagx="lpage" title="lpage">182</span><span class="pub-id"><a href="https://dx.doi.org/10.1089/can.2017.0027">10.1089/can.2017.0027</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29082314">29082314</a></span></span></li> <li tag="ref"><a name="B36-molecules-25-04821" /><span class="label" tagx="label" title="label">36.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Brunetti</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pichini</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pacifici</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">BusardÃ²</span><span class="given-names" tagx="given-names" title="given-names">F.P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">del Rio</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Herbal Preparations of Medical Cannabis: A Vademecum for Prescribing Doctors</span><span class="source" tagx="source" title="source">Medicina</span><span class="year" tagx="year" title="year">2020</span><span class="volume" tagx="volume" title="volume">56</span><span class="elocation-id" tagx="elocation-id" title="elocation-id">237</span><span class="pub-id"><a href="https://dx.doi.org/10.3390/medicina56050237">10.3390/medicina56050237</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32429074">32429074</a></span></span></li> <li tag="ref"><a name="B37-molecules-25-04821" /><span class="label" tagx="label" title="label">37.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Koltai</span><span class="given-names" tagx="given-names" title="given-names">H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Poulin</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Namdar</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Promoting cannabis products to pharmaceutical drugs</span><span class="source" tagx="source" title="source">Eur. J. Pharm. Sci.</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">132</span><span class="fpage" tagx="fpage" title="fpage">118</span><span class="lpage" tagx="lpage" title="lpage">120</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.ejps.2019.02.027">10.1016/j.ejps.2019.02.027</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30851400">30851400</a></span></span></li> <li tag="ref"><a name="B38-molecules-25-04821" /><span class="label" tagx="label" title="label">38.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Szarka</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Geophysical aspects of man-made electromagnetic noise in the earthâ€"A review</span><span class="source" tagx="source" title="source">Surv. Geophys.</span><span class="year" tagx="year" title="year">1988</span><span class="volume" tagx="volume" title="volume">9</span><span class="fpage" tagx="fpage" title="fpage">287</span><span class="lpage" tagx="lpage" title="lpage">318</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/BF01901627">10.1007/BF01901627</a></span></span></li> <li tag="ref"><a name="B39-molecules-25-04821" /><span class="label" tagx="label" title="label">39.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pertwee</span><span class="given-names" tagx="given-names" title="given-names">R.G.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Î"9-tetrahydrocannabinol, cannabidiol and Î"9-tetrahydrocannabivarin</span><span class="source" tagx="source" title="source">Br. J. Pharmacol.</span><span class="year" tagx="year" title="year">2008</span><span class="volume" tagx="volume" title="volume">153</span><span class="fpage" tagx="fpage" title="fpage">199</span><span class="lpage" tagx="lpage" title="lpage">215</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/sj.bjp.0707442">10.1038/sj.bjp.0707442</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17828291">17828291</a></span></span></li> <li tag="ref"><a name="B40-molecules-25-04821" /><span class="label" tagx="label" title="label">40.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Di Marzo</span><span class="given-names" tagx="given-names" title="given-names">V.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Piscitelli</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The endocannabinoid system and its modulation by phytocannabinoids</span><span class="source" tagx="source" title="source">Neurotherapeutics</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">12</span><span class="fpage" tagx="fpage" title="fpage">692</span><span class="lpage" tagx="lpage" title="lpage">698</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s13311-015-0374-6">10.1007/s13311-015-0374-6</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26271952">26271952</a></span></span></li> <li tag="ref"><a name="B41-molecules-25-04821" /><span class="label" tagx="label" title="label">41.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Corroon</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Felice</span><span class="given-names" tagx="given-names" title="given-names">J.F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The endocannabinoid system and its modulation by cannabidiol (CBD)</span><span class="source" tagx="source" title="source">Altern. Ther. Health Med.</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">25</span><span class="fpage" tagx="fpage" title="fpage">6</span><span class="lpage" tagx="lpage" title="lpage">14</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31202198">31202198</a></span></span></li> <li tag="ref"><a name="B42-molecules-25-04821" /><span class="label" tagx="label" title="label">42.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bisogno</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">HanuÅ¡</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">De Petrocellis</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tchilibon</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ponde</span><span class="given-names" tagx="given-names" title="given-names">D.E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Brandi</span><span class="given-names" tagx="given-names" title="given-names">I.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Moriello</span><span class="given-names" tagx="given-names" title="given-names">A.S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Davis</span><span class="given-names" tagx="given-names" title="given-names">J.B.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mechoulam</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Di Marzo</span><span class="given-names" tagx="given-names" title="given-names">V.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide</span><span class="source" tagx="source" title="source">Br. J. Pharmacol.</span><span class="year" tagx="year" title="year">2001</span><span class="volume" tagx="volume" title="volume">134</span><span class="fpage" tagx="fpage" title="fpage">845</span><span class="lpage" tagx="lpage" title="lpage">852</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/sj.bjp.0704327">10.1038/sj.bjp.0704327</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11606325">11606325</a></span></span></li> <li tag="ref"><a name="B43-molecules-25-04821" /><span class="label" tagx="label" title="label">43.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Massi</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Valenti</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vaccani</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gasperi</span><span class="given-names" tagx="given-names" title="given-names">V.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Perletti</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Marras</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fezza</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Maccarrone</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Parolaro</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid</span><span class="source" tagx="source" title="source">J. Neurochem.</span><span class="year" tagx="year" title="year">2008</span><span class="volume" tagx="volume" title="volume">104</span><span class="fpage" tagx="fpage" title="fpage">1091</span><span class="lpage" tagx="lpage" title="lpage">1100</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/j.1471-4159.2007.05073.x">10.1111/j.1471-4159.2007.05073.x</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18028339">18028339</a></span></span></li> <li tag="ref"><a name="B44-molecules-25-04821" /><span class="label" tagx="label" title="label">44.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Blasco-Benito</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Seijo-Vila</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Caro-Villalobos</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tundidor</span><span class="given-names" tagx="given-names" title="given-names">I.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Andradas</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">GarcÃ­a-Taboada</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wade</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Smith</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">GuzmÃ¡n</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">PÃ©rez-GÃ³mez</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Appraising the â€œentourage effectâ€�: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer</span><span class="source" tagx="source" title="source">Biochem. Pharmacol.</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">157</span><span class="fpage" tagx="fpage" title="fpage">285</span><span class="lpage" tagx="lpage" title="lpage">293</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.bcp.2018.06.025">10.1016/j.bcp.2018.06.025</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29940172">29940172</a></span></span></li> <li tag="ref"><a name="B45-molecules-25-04821" /><span class="label" tagx="label" title="label">45.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pacifici</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Marchei</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Salvatore</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guandalini</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">BusardÃ²</span><span class="given-names" tagx="given-names" title="given-names">F.P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pichini</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Evaluation of long-term stability of cannabinoids in standardized preparations of cannabis flowering tops and cannabis oil by ultra-high-performance liquid chromatography tandem mass spectrometry</span><span class="source" tagx="source" title="source">Clin. Chem. Lab Med.</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">56</span><span class="fpage" tagx="fpage" title="fpage">94</span><span class="lpage" tagx="lpage" title="lpage">96</span><span class="pub-id"><a href="https://dx.doi.org/10.1515/cclm-2017-0758">10.1515/cclm-2017-0758</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29176009">29176009</a></span></span></li> <li tag="ref"><a name="B46-molecules-25-04821" /><span class="label" tagx="label" title="label">46.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pavlovic</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nenna</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Calvi</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Panseri</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Borgonovo</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Giupponi</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cannazza</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Giorgi</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Quality traits of â€œcannabidiol oilsâ€�: Cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations</span><span class="source" tagx="source" title="source">Molecules</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">23</span><span class="elocation-id" tagx="elocation-id" title="elocation-id">1230</span><span class="pub-id"><a href="https://dx.doi.org/10.3390/molecules23051230">10.3390/molecules23051230</a></span></span></li> <li tag="ref"><a name="B47-molecules-25-04821" /><span class="label" tagx="label" title="label">47.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Velez</span><span class="given-names" tagx="given-names" title="given-names">L.I.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Oâ€™Connell</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rice</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Benitez</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">LoVecchio</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Adverse reactions to cannabis and cannabinoids</span><span class="source" tagx="source" title="source">Emerg. Med. Rep.</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">39</span><span class="fpage" tagx="fpage" title="fpage">20</span></span></li> <li tag="ref"><a name="B48-molecules-25-04821" /><span class="label" tagx="label" title="label">48.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Geller</span><span class="given-names" tagx="given-names" title="given-names">A.I.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shehab</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Weidle</span><span class="given-names" tagx="given-names" title="given-names">N.J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lovegrove</span><span class="given-names" tagx="given-names" title="given-names">M.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wolpert</span><span class="given-names" tagx="given-names" title="given-names">B.J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Timbo</span><span class="given-names" tagx="given-names" title="given-names">B.B.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mozersky</span><span class="given-names" tagx="given-names" title="given-names">R.P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Budnitz</span><span class="given-names" tagx="given-names" title="given-names">D.S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Emergency department visits for adverse events related to dietary supplements</span><span class="source" tagx="source" title="source">N. Engl. J. Med.</span><span class="year" tagx="year" title="year">2015</span><span class="volume" tagx="volume" title="volume">373</span><span class="fpage" tagx="fpage" title="fpage">1531</span><span class="lpage" tagx="lpage" title="lpage">1540</span><span class="pub-id"><a href="https://dx.doi.org/10.1056/NEJMsa1504267">10.1056/NEJMsa1504267</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26465986">26465986</a></span></span></li> <li tag="ref"><a name="B49-molecules-25-04821" /><span class="label" tagx="label" title="label">49.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bushra</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aslam</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khan</span><span class="given-names" tagx="given-names" title="given-names">A.Y.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Food-Drug Interactions</span><span class="source" tagx="source" title="source">Oman Med. J.</span><span class="year" tagx="year" title="year">2011</span><span class="volume" tagx="volume" title="volume">26</span><span class="fpage" tagx="fpage" title="fpage">77</span><span class="lpage" tagx="lpage" title="lpage">83</span><span class="pub-id"><a href="https://dx.doi.org/10.5001/omj.2011.21">10.5001/omj.2011.21</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22043389">22043389</a></span></span></li> <li tag="ref"><a name="B50-molecules-25-04821" /><span class="label" tagx="label" title="label">50.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fonseca</span><span class="given-names" tagx="given-names" title="given-names">B.M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Correia-Da-Silva</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Teixeira</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Inspired by Nature: Modern Medicines Derived from Cannabis</span><span class="source" tagx="source" title="source">Front. Nat. Prod. Chem.</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">4</span><span class="fpage" tagx="fpage" title="fpage">119</span><span class="lpage" tagx="lpage" title="lpage">155</span></span></li> <li tag="ref"><a name="B51-molecules-25-04821" /><span class="label" tagx="label" title="label">51.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jiang</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yamaori</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Takeda</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yamamoto</span><span class="given-names" tagx="given-names" title="given-names">I.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Watanabe</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes</span><span class="source" tagx="source" title="source">Life Sci.</span><span class="year" tagx="year" title="year">2011</span><span class="volume" tagx="volume" title="volume">89</span><span class="fpage" tagx="fpage" title="fpage">165</span><span class="lpage" tagx="lpage" title="lpage">170</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.lfs.2011.05.018">10.1016/j.lfs.2011.05.018</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21704641">21704641</a></span></span></li> <li tag="ref"><a name="B52-molecules-25-04821" /><span class="label" tagx="label" title="label">52.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Antoniou</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bodkin</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ho</span><span class="given-names" tagx="given-names" title="given-names">J.M.-W.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Drug interactions with cannabinoids</span><span class="source" tagx="source" title="source">Can. Med Assoc. J.</span><span class="year" tagx="year" title="year">2020</span><span class="volume" tagx="volume" title="volume">192</span><span class="fpage" tagx="fpage" title="fpage">E206</span><span class="pub-id"><a href="https://dx.doi.org/10.1503/cmaj.191097">10.1503/cmaj.191097</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32122975">32122975</a></span></span></li> <li tag="ref"><a name="B53-molecules-25-04821" /><span class="label" tagx="label" title="label">53.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jiang</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yamaori</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Okamoto</span><span class="given-names" tagx="given-names" title="given-names">Y.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yamamoto</span><span class="given-names" tagx="given-names" title="given-names">I.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Watanabe</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19</span><span class="source" tagx="source" title="source">Drug Metab. Pharmacokinet.</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">28</span><span class="fpage" tagx="fpage" title="fpage">332</span><span class="lpage" tagx="lpage" title="lpage">338</span><span class="pub-id"><a href="https://dx.doi.org/10.2133/dmpk.DMPK-12-RG-129">10.2133/dmpk.DMPK-12-RG-129</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23318708">23318708</a></span></span></li> <li tag="ref"><a name="B54-molecules-25-04821" /><span class="label" tagx="label" title="label">54.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Brown</span><span class="given-names" tagx="given-names" title="given-names">J.D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Winterstein</span><span class="given-names" tagx="given-names" title="given-names">A.G.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Potential Adverse Drug Events and Drugâ€"Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use</span><span class="source" tagx="source" title="source">J. Clin. Med.</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">8</span><span class="elocation-id" tagx="elocation-id" title="elocation-id">989</span><span class="pub-id"><a href="https://dx.doi.org/10.3390/jcm8070989">10.3390/jcm8070989</a></span></span></li> <li tag="ref"><a name="B55-molecules-25-04821" /><span class="label" tagx="label" title="label">55.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alsherbiny</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">C.G.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Medicinal Cannabisâ€"Potential Drug Interactions</span><span class="source" tagx="source" title="source">Medicines</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">6</span><span class="elocation-id" tagx="elocation-id" title="elocation-id">3</span><span class="pub-id"><a href="https://dx.doi.org/10.3390/medicines6010003">10.3390/medicines6010003</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30583596">30583596</a></span></span></li> <li tag="ref"><a name="B56-molecules-25-04821" /><span class="label" tagx="label" title="label">56.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Arnold</span><span class="given-names" tagx="given-names" title="given-names">W.R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Weigle</span><span class="given-names" tagx="given-names" title="given-names">A.T.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Das</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2</span><span class="source" tagx="source" title="source">J. Inorg. Biochem.</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">184</span><span class="fpage" tagx="fpage" title="fpage">88</span><span class="lpage" tagx="lpage" title="lpage">99</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.jinorgbio.2018.03.016">10.1016/j.jinorgbio.2018.03.016</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29689453">29689453</a></span></span></li> <li tag="ref"><a name="B57-molecules-25-04821" /><span class="label" tagx="label" title="label">57.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bettiol</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lombardi</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Crescioli</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Maggini</span><span class="given-names" tagx="given-names" title="given-names">V.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gallo</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mugelli</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Firenzuoli</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baronti</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vannacci</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Galenic Preparations of Therapeutic Cannabis sativa Differ in Cannabinoids Concentration: A Quantitative Analysis of Variability and Possible Clinical Implications</span><span class="source" tagx="source" title="source">Front. Pharmacol.</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">9</span><span class="pub-id"><a href="https://dx.doi.org/10.3389/fphar.2018.01543">10.3389/fphar.2018.01543</a></span></span></li> <li tag="ref"><a name="B58-molecules-25-04821" /><span class="label" tagx="label" title="label">58.</span><span class="element-citation'"><span class="mixed-article-title" title="mixed-article-title">Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products. Final guidance, January 2017, U.S. Department of Health and Human Services, Food and Drug Administration</span><span class="comment">Available online: <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-requirements-combination-products">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-requirements-combination-products</a></span><span class="date-in-citation" tagx="date-in-citation" title="date-in-citation">(accessed on 18 January 2017)</span></span></li> <li tag="ref"><a name="B59-molecules-25-04821" /><span class="label" tagx="label" title="label">59.</span><span class="element-citation'"><span class="mixed-article-title" title="mixed-article-title">FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)</span><span class="comment">Available online: <a href="https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd">https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd</a></span><span class="date-in-citation" tagx="date-in-citation" title="date-in-citation">(accessed on 10 January 2020)</span></span></li> <li tag="ref"><a name="B60-molecules-25-04821" /><span class="label" tagx="label" title="label">60.</span><span class="element-citation'"><span class="mixed-article-title" title="mixed-article-title">The drug review and approval process in Canada. An e-guide</span><span class="comment">Available online: <a href="https://spharm-inc.com/the-drug-review-and-approval-process-in-canada-an-eguide/">https://spharm-inc.com/the-drug-review-and-approval-process-in-canada-an-eguide/</a></span><span class="date-in-citation" tagx="date-in-citation" title="date-in-citation">(accessed on 10 January 2020)</span></span></li> </ul> </div> </div> <div class="floats-group" title="floats-group"> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 1</span></a></div>   <p>Illustration of concepts associated with the development of cannabis-related pharmaceutical drugs. Cannabis-inspired drugs, cannabinergic drugs, or cannabis-based drugs are to be developed while interaction(s) between phytocannabinoids or synthetic cannabinoids and the endocannabinoid system should be examined. Drug review and approval process steps should be taken.</p>   </div> <div class="table-wrap_UNKNOWN" id="molecules-25-04821-t001" orientation="portrait" position="float">
molecules-25-04821-t001_Table 1<span class="label" tagx="label" title="label">Table 1</span> <p>Cannabis-inspired or -based medicines available today and their pharmaceutical status. FDA, Food and Drug Administration; THC, Î"9-tetrahydrocannabinol; CBD, cannabidiol; CBN, cannabinol; CYP, Cytochrome P450; EU, European Union; UGT, uridine 5â€² diphospho-glucuronosyltransferase.</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Name</th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Basic Formulation</th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Studies</th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Proved Efficacy</th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Key Limiting Toxicity</th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Recommended Dosage </th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drugâ€"Drug Interactions Reported</th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Approval</th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th> </tr> </thead> <tbody> <tr> <td colspan="10" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Drugs of one molecule</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MARINOL<sup>Â®</sup> (GW Pharmaceuticals, Cambridge, UK)</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Appetite stimulation; antiemetic associated with cancer chemotherapy</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dronabinol (synthetic THC)</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 mg/day<br /><br />or 30 mg/kg</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Appetite stimulation: 2.5 mg twice daily; antiemetic: 5 mg 3â€"4 times daily</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" /> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B16-molecules-25-04821">16</a>]</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EPIDIOLEX<sup>Â®</sup> (GW Pharmaceuticals)</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lennoxâ€"Gastaut syndrome and Dravet syndrome in patients </td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plant derived CBD</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 mg/kg/day</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5â€"20 mg/kg/day </td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP1A2, CYP2B6<br /><br />substrates, uridine 5â€™ diphospho-glucuronosyltransferase 1A9 (UGT1A9) and UGT2B7. <br /><br />CYP2C8 and CYP2C9 substrates</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B17-molecules-25-04821">17</a>]</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SYNDROS<sup>Â®</sup> (Benuvia Therapeutics Inc, Chandler, AZ, USA)</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anorexia; nausea and vomiting associated with cancer chemotherapy</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dronabinol (synthetic THC)</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes </td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 mg/day</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2 mg/day </td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropsychiatric adverse reactions; hemodynamic instability</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B18-molecules-25-04821">18</a>]</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CESAMET<sup>Â®</sup> (Valeant Pharma Int, Laval, QC, Canada)</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nausea and vomiting induced<br /><br />by cancer chemotherapy</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nabilone<br /><br />(synthetic THC)</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" /> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" /> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 mg/day</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diazepam 5 mg; sodium secobarbital 100 mg;<br /><br />alcohol (absolute) 45 mL; codeine 65 mg</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B19-molecules-25-04821">19</a>]</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">INM-755 cream (Inmed pharma, Vancouver, BC, Canada)</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skin diseases and wounds; epidermolysis bullosa</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria <i>Escherichia coli</i> fermentation derived from one rare CBN (Cannabinol)</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes Phase 1â€"2 ongoing</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" /> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses of INM-755 cream are currently being tested</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" /> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" /> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B20-molecules-25-04821">20</a>]</td> </tr> <tr> <td colspan="10" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Drugs of combinatoric formulations</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SATIVEX<sup>Â®</sup> Oromucosal spray (GW Pharmaceuticals)</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain relief</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plant-derived CBD:THC and terpenes</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90 mg/day</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5â€"60 mg/day</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reversible inhibitor of CYP3A4, 1A2, 2B6, 2C9, and 2C19</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EU, Canada</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B21-molecules-25-04821">21</a>]</td> </tr> </tbody> </table> </div> <div class="table-wrap_UNKNOWN" id="molecules-25-04821-t002" orientation="portrait" position="float">
molecules-25-04821-t002_Table 2<span class="label" tagx="label" title="label">Table 2</span> <p>The general drug review and approval process steps. DDIs, drugâ€"drug interactions.</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stage</th> <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Activities</th> </tr> </thead> <tbody> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1. Initial drug research</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Discovering and identifying various chemical and biological substances or other products on the way toward developing a drug; testing for activity, efficacy, toxicity, and ultimately gathering preliminary information on its effectiveness and safety. If the results are promising, researchers proceed to the next stage of development.</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2. Preclinical studies</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Administration of the drug to selected species of animals (in vivo) or cells (in vitro). The drug must be shown to cause no serious harm (toxicity) at the doses required to have an effect either in a single compound or in DDIs. If results from these initial studies are promising and further tests show acceptable safety levels and clear or potential efficacy, then the next step would be to submit a clinical trial application.</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3. Clinical trials</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The results of clinical trials conducted with humans are key components of the review process by the regulatory agency. The purpose of a trial is to gather clinical information about a drugâ€™s effectiveness and safety, determine best dosing/usage in humans, evaluate any adverse drug reactions and DDIs, and compare results to already existing treatments for the same disease or condition or to placebo when no treatment already exists for the aimed pathology (when ethically possible). The information gathered from these trials is then included in the dossiers to be reviewed by the relevant agencies.</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4. Drug approval process</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">If results of all the preclinical studies and the clinical trials show that a drugâ€™s potential therapeutic benefit outweighs its risks (side effects, toxicity, etc.), and the chemistry and manufacturing dossier is complete, then the sponsor may decide to file a new drug submission (NDS) with the appropriate regulatory agency in order to be granted authorization to sell the drug in the country.</td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5. After approval</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The regulatory agency requires a sponsor to ensure that the use of its drug is done under the terms of its market authorization. In addition, life cycle management activities (post-approval submissions, for new indications, new dosage forms, new strengths, manufacturing changes, etc.) are required to ensure the maintenance of the product license with its related improvements. In summary, sponsors need to ensure its continued compliance with the food and drug regulations while their products are on the market.<br /><br />On the other hand, the regulatory agency monitors drug information and adverse drug reaction reporting, conducts market surveillance, investigates complaints, and manages recalls if necessary, amongst other things. </td> </tr> <tr> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6. Additional regulations</td> <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">There are also more processes and regulations to follow and consider before, during, or after the review process, and before the drug is officially marketed, distributed, and sold in a country. Topics included licensing, warehousing, wholesale distribution rules, and the Drug Establishment License (DEL), as well as regulations around distribution to consumers, regulations around the marketing and advertising activities, provincial requirements, and health insurance funding rules, among others.</td> </tr> </tbody> </table> </div> </div>  </body></html>